Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic (OTCMKTS:BVNRY) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 1,795 shares, a decline of 31.6% from the June 30th total of 2,625 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 4,660 shares, the short-interest ratio is currently 0.4 days.

Bavarian Nordic Stock Performance

Shares of BVNRY opened at $9.12 on Friday. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $13.00. The company’s 50 day simple moving average is $9.32 and its 200 day simple moving average is $9.78. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 12.00 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last released its earnings results on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $165.70 million during the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.32%.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.